Clinical Trials
15 trialsNCT04337177 2026-05-11
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Active not recruiting
NCT05106296 2026-01-09
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Augusta University
Phase 1 Recruiting
NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT00138216 2023-10-02
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT02502708 2020-06-04
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Lumos Pharma
Phase 1 Completed
NCT00994071 2019-12-09
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01119599 2015-09-29
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00020150 2015-04-29
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00946335 2014-07-09
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00052780 2013-09-30
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00077454 2013-06-05
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01076530 2013-05-03
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00544284 2013-02-15
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
Phase 1 Completed
NCT00303940 2012-03-15
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00025558 2011-03-28
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
NYU Langone Health
Phase 1 Completed